Technology

Optimized for actionability

Delve Decide’s bioinformatic pipeline, curated pathogen database and clinical interpretation software are robust, fast and reliable. Delve Decide rapidly analyzes DNA and RNA, sorting millions of sequences to identify the genetic signatures of potential pathogens using a broad, curated database, delivering comprehensive microbial analysis impossible through conventional hypothesis-guided testing.

World-class genomic sequencing

Delve Bio has partnered with Broad Clinical Labs, a CLIA-licensed and CAP-accredited, wholly owned subsidiary of the Broad Institute of MIT and Harvard for sample processing and sequencing. Broad Clinical Labs brings more than three decades of experience at the cutting edge of genomic research and application to all Delve’s customers.

Learn more

Generate optimized sequence data

Specialized sample processing includes enrichment for RNA viruses and DNA viruses, bacterial, fungi and parasites. The process is optimized for sensitivity, specificity, and contamination-free sequence data

Detect potential pathogen sequences

Preprocessing filtering and human host background subtraction quickly focuses on potential pathogens.

Identify likely pathogens

A custom-curated database covering more than 68,000 known and emerging pathogens, followed by additional filtering and taxonomic classification identifies pathogens present.

Automated identification

Automated bioinformatics identifies virus RNA and DNA, as well as bacterium, fungus and parasite DNA.

Decide next steps

Automated results reporting, including a heat map or read counts and a graphical interface of aligned counts, interpreted by our expert clinicians provides actionable information to guide clinical next steps.

Detect, identify and decide

Delve Decide is the proprietary platform that powers Delve Bio’s metagenomic testing, built to deliver unrivaled accuracy, reliability and speed.